Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Shows Promise With Anti-Cancer Drug

Boston, MA 10/29/2013 (wallstreetpr) – Shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) plummeted to as low as $5.10 hours after the USA-based drug manufacturer presented positive one-year follow-up results from its GALAXY-1 trial of its ambitious anti-cancer innovation Ganetespib at the 15th World Conference on Lung Cancer (WCLC) in Sydney, Australia. GALAXY-1 is Synta Pharmaceutical’s (Synta) ambitious global, […]